Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Ketamine for Drug Resistant Epilepsy
NCT05019885Phase 2Completed
- Start
- Aug 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in epilepsy. Primary endpoints: Number of participants with seizure reduction at 28 days and Seizure frequency at 3 months. Started Aug 2022; status: completed.
02
Drugs
ketamine
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05019885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05019885.